Details for Patent: 9,216,179
✉ Email this page to a colleague
Which drugs does patent 9,216,179 protect, and when does it expire?
Patent 9,216,179 protects DUZALLO and ZURAMPIC and is included in two NDAs.
This patent has eighteen patent family members in seventeen countries.
Summary for Patent: 9,216,179
| Title: | Treatment of gout and hyperuricemia |
| Abstract: | Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylt- hio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described. |
| Inventor(s): | Miner; Jeffrey (San Diego, CA), Girardet; Jean-Luc (San Diego, CA), Quart; Barry D. (Encinitas, CA) |
| Assignee: | ARDEA BIOSCIENCES, INC. (San Diego, CA) |
| Application Number: | 13/704,192 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,216,179
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-001 | Aug 18, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE | ⤷ Sign Up | ||||
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-002 | Aug 18, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE | ⤷ Sign Up | ||||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15% | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,216,179
| PCT Information | |||
| PCT Filed | June 14, 2011 | PCT Application Number: | PCT/US2011/040398 |
| PCT Publication Date: | December 22, 2011 | PCT Publication Number: | WO2011/159732 |
International Family Members for US Patent 9,216,179
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2582683 | ⤷ Sign Up | 2019008 | Norway | ⤷ Sign Up |
| Canada | 2802407 | ⤷ Sign Up | |||
| Cyprus | 1120473 | ⤷ Sign Up | |||
| Denmark | 2582683 | ⤷ Sign Up | |||
| Spain | 2670700 | ⤷ Sign Up | |||
| Croatia | P20180780 | ⤷ Sign Up | |||
| Hungary | E038265 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
